Portal de Periódicos da CAPES

The diagnosis of cystic fibrosis

2017; Elsevier BV; Volume: 46; Issue: 6 Linguagem: Inglês

10.1016/j.lpm.2017.04.010

2213-0276

K. De Boeck, F. Vermeulen, Lieven Dupont,

Tracheal and airway disorders

Establishing the diagnosis of cystic fibrosis (CF) is straight forward in the majority of patients: they present with a clear clinical picture (most frequently chronic respiratory symptoms plus malabsorption), the sweat chloride value is > 60 mmol/L and two known disease causing CFTR mutations are identified. In less than 5% of subjects, mainly those with a milder or limited phenotype, the diagnostic process is more complex, because initial diagnostic test results are inconclusive: sweat chloride concentration in the intermediate range, less than 2 CF causing mutations identified or both. These patients should be referred to expert centers where bioassays of CFTR function like nasal potential difference measurement or intestinal current measurement can be done. Still, in some patients, despite symptoms compatible with CF and some indication of CFTR dysfunction (e.g. only intermediate sweat chloride value), diagnostic criteria are not met (e.g. only 1 CFTR mutation identified). For these subjects, the term CFTR related disorder (CFTR-RD) is used. Patients with disseminated bronchiectasis, congenital bilateral absence of the vas deferens and acute or recurrent pancreatitis may fall in this category. CF has a very wide disease spectrum and increasingly the diagnosis is being made during adult life, mainly in subjects with milder phenotypes. In many countries, nationwide CF newborn screening (NBS) has been introduced. In screen positive babies, the diagnosis of CF must be confirmed by a sweat test demonstrating a sweat chloride concentration above 60 mmol/L. To achieve the benefit of NBS, every baby in whom the diagnosis of CF is confirmed must receive immediate follow-up and treatment in a CF reference center. CF NBS is not full proof: some diagnoses will be missed and in some babies the diagnosis cannot be confirmed nor ruled out with certainty. Screening algorithms that include gene sequencing will detect a high number of such babies that are screen positive with an inconclusive diagnosis (CFSPID). Even in 2016, the most reliable and widely available diagnostic test for CF is the measurement of chloride concentration in sweat. The method of choice is sweat induction by pilocarpine iontophoresis, followed by sweat collection on a gauze or filter paper or in a Macroduct coil. Since mutation specific therapies have become available, it is important to identify the mutations responsible for CF in each individual patient.GlossaryCFcystic fibrosisCFSPIDcystic fibrosis screen positive inconclusive diagnosisCFTRcystic fibrosis transmembrane regulatorCFTR-RDcystic fibrosis transmembrane regulator related disorderECFSPREuropean cystic fibrosis society patient registryENaCEpithelial sodium channelFISforskolin induced swellingICMintestinal current measurementIRTimmunoreactive trypsinogenNBSnewborn screeningNPDnasal potential difference Glossary cystic fibrosis cystic fibrosis screen positive inconclusive diagnosis cystic fibrosis transmembrane regulator cystic fibrosis transmembrane regulator related disorder European cystic fibrosis society patient registry Epithelial sodium channel forskolin induced swelling intestinal current measurement immunoreactive trypsinogen newborn screening nasal potential difference